AcquisitionsMar 30, 2026, 06:03 AM
Novartis to Acquire Avidity Biosciences for $12 Billion, Boosting Neuroscience Pipeline and Sales Growth
AI Summary
Novartis has agreed to acquire Avidity Biosciences for $12 billion in cash, gaining access to Avidity's RNA therapeutics platform and late-stage neuroscience programs. The acquisition is expected to strengthen Novartis' neuroscience franchise, unlock multi-billion-dollar opportunities, and raise the company's expected 2024-2029 sales CAGR from +5% to +6%.
Key Highlights
- Novartis will acquire Avidity Biosciences, an RNA therapeutics innovator, for $12 billion in cash.
- The acquisition strengthens Novartis' neuroscience franchise with three late-stage programs targeting genetic neuromuscular diseases.
- It advances Novartis' xRNA strategy by adding Avidity's Antibody Oligonucleotide Conjugates (AOCs™) platform.
- The deal is expected to unlock multi-billion-dollar opportunities with planned product launches before 2030.
- Novartis raises its expected 2024-2029 sales CAGR from +5% to +6% due to the acquisition.
- Avidity will separate its early-stage precision cardiology programs into a new company prior to closing.
- Closing is expected in H1 2026, subject to customary conditions.